About mineralys therapeutics inc - MLYS
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
MLYS At a Glance
Mineralys Therapeutics, Inc.
150 North Radnor Chester Road
Radnor, Pennsylvania 19087
| Phone | 1-888-378-6240 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -177,810,000.00 | |
| Sector | Health Technology | Employees | 51 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
MLYS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 3.207 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.076 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
MLYS Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -3,486,470.588 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
MLYS Liquidity
| Current Ratio | 14.021 |
| Quick Ratio | 14.021 |
| Cash Ratio | 13.532 |
MLYS Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -77.725 |
| Return on Equity | -82.241 |
| Return on Total Capital | -92.969 |
| Return on Invested Capital | -82.241 |
MLYS Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |